Latest News

National Organization for Rare Disorders (NORD®) Founder and past President Abbey S. Meyers, PhD, former U.S. Rep. Jaime Herrera Beutler of Washington State, New York Yankees centerfielder Bernie Williams, and pioneer clinical geneticist, Dr. Ada Hamosh, headline a group of rare disease champions who will be honored for their outstanding...
Tsukuba, Japan — Atherosclerosis, a chronic condition characterized by the accumulation of lipid and inflammatory cells within the blood vessel walls, causes cardiovascular diseases, such as heart disease and stroke. Natto, a food rich in vitamin K2, has shown promise in mitigating cardiovascular diseases by enhancing arterial flexibility and modulating...
Tampa, Florida — Researchers affiliated with Natura Therapeutics, Inc., Tampa, Florida, and the University of South Florida (USF) have jointly received a one-year, $110,000 Small Business Innovation Research (SBIR) grant from the National Institutes of Health’s (NIH) National Center for Complementary and Alternative Medicine to continue studying TeaMem™, a compound...
SAN DIEGO – The editors of Nature Biotechnology recently published an editorial entitled “Ultra-precision medicine” in the June 2021 issue of Nature Biotechnology[i], highlighting new initiatives in n-of-1 drug development, as well as the rapid progress that n-Lorem Foundation, a nonprofit organization providing the ultra-rare disease community with free, lifetime supplies...
TORONTO, Canada – Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the publication in Nature Communications of new research from a scientific team at the Ottawa Hospital Research Institute (OHRI) that validates the company’s novel...
NAARDEN, Netherlands, WALTHAM, Mass. & BARCELONA, Spain — Prilenia Therapeutics B.V. and Ferrer today announced the publication, in the journal Nature Medicine, of a manuscript entitled “Pridopidine in Early-Stage Manifest Huntington Disease: A Phase 3 Trial“ii. The publication describes data showing that treatment with pridopidine slowed clinical progression in Huntington’s disease (HD)...